U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Piperacillin Tazobactam – Injection products
  1. Development Resources

Piperacillin Tazobactam – Injection products

Exceptions or additions to the recognized standards

 

Minimum Inhibitory
Concentrations
(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Enterobacteralesa

≤8/4

16/4

≥32/4

≥25

21-24

≤20

S = Susceptible; I = Intermediate; R = Resistant

a Clinical efficacy was shown for E. coli and K. pneumoniae

For the bacteria listed below, susceptibility test interpretive criteria are not recognized at this time:

Other Non-Enterobacterales

Back to Top